Evidence map›Paper›PMID 42134908›Full record

ReviewBMJ global health2026

Reaching the margins: examining equity in Indonesia's COVID-19 vaccination strategy.

Olivia Herlinda, Sayyid Muhammad Jundullah, Diah Satyani Saminarsih

Abstract readReview
In one paragraph

Review in BMJ global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Olivia HerlindaCenter for Indonesia's Strategic Development Initiatives, Central Jakarta, Jakarta, Indonesia olivia.herlinda@lshtm.ac.uk.ORCID 0000-0002-4353-3646
Sayyid Muhammad JundullahCenter for Indonesia's Strategic Development Initiatives, Central Jakarta, Jakarta, Indonesia.
Diah Satyani SaminarsihCenter for Indonesia's Strategic Development Initiatives, Central Jakarta, Jakarta, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic profoundly affected health, social and economic systems worldwide. In less than a year, COVID-19 vaccines were developed and distributed. However, global and national distribution efforts faced significant challenges in ensuring equitable access, particularly for vulnerable populations. Despite WHO guidelines for national vaccine allocation, governments encountered difficulties in vaccine allocation and prioritisation. While Indonesia's COVID-19 primary dose coverage surpassed 70%, disparities persisted both across and within provinces as well as among different population groups. Discussion about the definition of vulnerable population and who should be prioritised remains critical to preparing for future pandemics. This paper argues for the establishment of clear guidelines for national governments on the allocation of vaccines, enabling timely action in future pandemics to prevent avoidable deaths and disabilities. Robust governance and data also remain a key area to improve. Drawing on Indonesia's experience with COVID-19, this paper offers recommendations for vaccine allocation during a respiratory pathogen pandemic.

Indexed as

COVID-19COVID-19 VaccinesPandemicsVaccinationHumansIndonesiaSARS-CoV-2COVID-19 VaccinesCOVID-19Global HealthVaccines

Identifiers

PMID42134908
PMCPMC13182319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.